Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver by Chinta, Shankar J. et al.
www.elsevier.com/locate/molbrainresMolecular Brain ResearcResearch report
Presence of splice variant forms of cytochrome P4502D1
in rat brain but not in liver
Shankar J. Chintaa,b, Harish V. Paia,b, Vijayalakshmi Ravindranatha,b,*
aDivision of Cellular and Molecular Neuroscience, National Brain Research Centre, Nainwal Mode, Manesar, 122050, Haryana, India
bDepartment of Neurochemistry, National Institute of Mental Health and Neurosciences, Hosur Road, Bangalore 560 029, India
Accepted 5 December 2004
Available online 12 February 2005Abstract
Cytochromes P450 (P450), a family of heme-containing proteins, is involved in the oxidative metabolism of both foreign and endogenous
compounds. Although liver is quantitatively the major organ involved in the metabolism of most xenobiotics, there is increasing evidence
that these enzymes are present in extrahepatic tissues, such as lung, kidney, brain, etc and they may contribute to the in situ metabolism of
xenobiotics in these organs. The possible relationship between genetic polymorphism seen in P4502D6 and incidence of neurodegenerative
diseases, such as Parkinson’s disease, has prompted the characterization of P4502D enzymes in rat brain. In the present study, we
demonstrate that P4502D1 (the rat homologue of human P4502D6) is constitutively expressed in rat brain and the mRNA and protein are
localized predominantly in neuronal cell population in the olfactory bulb, cortex, cerebellum, and hippocampus. An alternate spliced
transcript of CYP2D1 having exon 3 deletion was detected in rat brain but not in liver. Deletion of exon 3 causes frame shift and generates a
stop codon at 391 bp relative to the start codon ATG leading to premature termination of translation. Thus, Northern blotting and in situ
hybridization represent contributions from functional transcripts and alternate spliced variants that do not translate into functional protein.
Further, the splice variant having partial inclusion of intron 6 detected in human brain was not detected in rat brain indicating that alternate
spliced gene products of P450 enzymes are generated in species-specific and tissue-specific manner.
D 2005 Elsevier B.V. All rights reserved.
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Cytochrome P450 (E.C. 1.14.14.1; P450) and associated
monooxygenases, a family of heme proteins, are the
principal class of drug metabolizing enzymes. They are
encoded by a supergene family and the member proteins
exist in multiple forms having distinct yet overlapping0169-328X/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: vijir@nbrc.ac.in (V. Ravindranath).substrate specificities. Multiple forms of P450, which are
selectively induced or inhibited by a variety of drugs, are
known to exist in liver, the major organ involved in P450-
mediated metabolism [8]. In recent years, there is increasing
evidence that these enzymes are present in extrahepatic
tissues such as lung, kidney, and brain and that they may
contribute to the metabolism of drugs and activation of
carcinogens and toxins in situ in the target tissue [3,13,23].
P450-mediated metabolism of psychoactive drugs directly
in the brain can lead to local pharmacological modulation at
the site of action and result in variable drug response. The
inter-individual variability in hepatic metabolism of drugsh 135 (2005) 81–92
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of P450, such as P4502D6, is reflected in the plasma levels
of administered drugs. But plasma drug levels often show
poor correlation with therapeutic effect [14] suggesting that
metabolism within the brain could influence the therapeutic
outcome regardless of hepatic clearance and plasma drug
levels. A moderate difference in the pharmacokinetics of
psychoactive drugs often leads to dramatic pharmacody-
namic effects suggesting that metabolism in situ within the
brain could play a significant role [5].
Over the past decade, studies from our laboratory and
others have demonstrated the presence of a competent
microsomal P450 system in the rodent [1,13,34] and human
[23,29] brain and its ability to metabolize a variety of
xenobiotics. The appearance of multiple forms of P450 in
brain and their selective inducibility by a variety of drugs
and xenobiotics has also been identified [1,2,33,36].
Significant differences are seen in the regulation and
function brain P450 enzymes compared to liver
[27,35,37]. For example, drugs, such as alprazolam, areFig. 1. Analysis of presence of exon 3 deletion in rat brain by RT-PCR. (A) RT-PCR
splice variants in rat brain shows the presence of the splice variant form in rat bra
cDNA. Lanes 3 and 4—PCR amplified product obtained using rat whole brain c
negative control performed without DNA template. dMT represents 0.5 Kb DNA la
data of the 200 bp RT-PCR product as depicted above. (C) The translated protei
termination of translation at amino acid 131 (represented by asterisk).metabolized variably in liver and brain wherein relatively
larger amount of the active metabolite is generated in rat
brain compared to liver [27]. These observations have
indicated the possible existence of unique P450 isoforms in
brain that are different from the well-characterized hepatic
P450s.
CYP2D is one of the major forms of P450 present in
both rat [17] and human brain [6]. In rats, five genes
belonging to the CYP2D family (CYP2D1, CYP2D2,
CYP2D3, CYP2D4, CYP2D5) have been described
[9,15,25], whereas in humans, one gene (CYP2D6) and
several pseudogenes (CYP2D7 and CYP2D8) are known
[24]. In humans, 5–10% of Caucasians exhibit defects in
CYP2D6 alleles with resultant decreased rates of metab-
olism of CYP2D6 substrates [10,11]. Sprague–Dawley
rats have a variant 2D1 allele, 2D1v, whereas Dark
Agouti rats have no detectable expression of 2D1 mRNA
in the liver [21].
Although CYP2D6 mRNA is mainly expressed in human
liver, it has also been detected in human brain [32];analyses using specific primers for detecting the presence of exon 3 deleted
in. Lanes 1 and 2—RT-PCR product (approximately 350 bp) using rat liver
DNA showing the presence of additional lower band (200 bp). Lane 5—
dder. (B) The mRNA sequence of CYP2D1 constructed from the sequence
n sequence of the exon 3 deleted form of rat brain showing the premature
Fig. 3. Northern blot analysis of rat brain total RNA using cDNA to
CYP2D1. Total RNA from rat liver (lane 1, 5 Ag) and rat brain cortex (lane
2, 12 Ag) were electrophoresed under denaturing conditions. After transfer
to nylon membrane, the blots were hybridized with antisense Riboprobe
prepared using cDNA to CYP2D1. The mobility of the 18 S and 28 S
ribosomal RNA is indicated. The CYP2D1 mRNA in rat brain was seen as
a band at approximately 1.6 kb.
Fig. 2. Analysis of presence of any splice variant having partial intron 6
inclusion in rat brain and liver by RT-PCR. RT-PCR analysis using specific
primers for detecting the presence of partial inclusion of intron 6 transcript
in rat brain (lanes 2 and 3) and rat liver (lanes 4 and 5). Human brain
autopsy sample from a subject expressing the partial inclusion of intron 6
(lane 6) was used as a positive control. This transcript could not be detected
in rat brain and liver. A PCR amplified product of about 280 bp long
representing the normally spliced CYP2D1 was detected in all the samples.
Lane 1 represents 0.5 kb DNA ladder.
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compared to livers.
Using RT-PCR CYP2D4 was shown to be the most
abundant CYP2D mRNA in rat brain [17] but the presence
of the protein could not be detected using the specific
antibody raised against P4502D4 even when 100 Ag of
microsomal protein was used [38].
Our earlier study has shown the occurrence of three
alternate spliced forms of CYP2D in human brain but not
in liver from the same individual. These clones have exon
3 deletion, partial inclusion of intron 6, or both [28]. The
alternate spliced variant having the inclusion of intron 6
alone generated an open-reading frame (GenBank Acces-
sion Number AY220845) and metabolized codeine pre-
dominantly to morphine, unlike the wild-type CYP2D6,
which forms nor-codeine as major metabolite. The alternate
spliced variants containing exon 3 deletion have a premature
stop codon, which prevents their translation into functional
gene products. Thus, estimation of P450 isoforms by
examining gene expression using Northern blotting, RT-
PCR, and in situ hybridization (6) would represent
contributions from functional and nonfunctional genes and
would potentially overestimate the expression of a particular
isoform.
In view of the important role that P4502D plays in the
metabolism of psychoactive drugs, and the inability to
detect the expression of P4502D4 in rat brain by earlier
studies and also recent report of splice variants for
CYP2D6 in human brain prompted us to investigated the
presence of splice variant forms of CYP2D in rat brainusing RT-PCR. Further, we have also analyzed the
expression and localization of P4502D1 in rat brain using
fluorescence in situ hybridization and immunohistochem-
istry and to assess the differences observed in the mRNA
expression and the protein content in rat brain.2. Materials and methods
2.1. Materials
cDNA to CYP2D1 and antiserum to P4502D1 were
obtained as gifts from Dr. J. P. Hardwick. DIG-RNA
labeling and detection kit, anti-digoxigenin fab fragments
linked to peroxidase and alkaline phosphatase were pur-
chased from Roche Biochemicals, USA. The tyramide
signal amplification (indirect) kit for in situ hybridization
was obtained from New England Nuclear, USA and
Vectastain-ABC Elite kit was purchased from Vector Labs,
USA. All other chemicals and reagents were of analytical
grade and were obtained from Sigma (St. Louis, MO, USA)
or Qualigens, India.
2.2. Animals
Male Wistar rats (3–4 months, 225–250 g) were obtained
from the Central Animal Research Facility of NIMHANS,
Bangalore, India. Animals had access to pelleted diet and
Fig. 4. Localization of CYP2D mRNA in control rat brain using fluorescent in situ hybridization. (A) In situ hybridization of coronal sections from rat brain
showing intense labeling of neurons in olfactory bulb. Scale bar = 200 Am. The arrow shows the presence of CYP2D mRNA in the neurons of the glomeruli,
which are depicted in inset. Scale bar = 25 Am. (B) No fluorescence staining was seen in control sections hybridized with sense probe. Scale bar = 200 Am.
(C) The presence of CYP2D mRNA in the neurons of cerebral cortex clearly shows differential staining in the laminar architecture of the cortex. Scale bar =
100 Am. (D) Control section hybridized with the sense probe did not show any staining. Scale bar = 100 Am. (E) Fluorescent labeling of Purkinje neurons
(arrow), granule cell layer (GL) and molecular layer (ML) of cerebellum. Scale bar = 100 Am. Inset depicting Purkinje neuron staining. Scale bar = 25 Am.
(F) Control section of rat cerebellum hybridized with the sense probe and counterstained with Evan’s blue is depicted. Scale bar = 200 Am. (G) The reticular
neurons (arrow) in the midbrain expressed the CYP2D mRNA. Scale bar = 100 Am. Inset shows the giant reticular neuron. Scale bar = 25 Am. (H) Sections
hybridized with sense Riboprobe showed no staining. Scale bar = 100 Am.
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Fig. 5. Localization of CYP2D mRNA in control rat brain using fluorescent in situ hybridization. (A) The granule cell layer of the dentate gyrus (arrow) was
intensely fluorescent. Intense fluorescence was seen in the CA1 pyramidal cell layer of hippocampus (double arrow). Arrowhead depicts the staining of CA3
neurons. (B) Control section hybridized with sense riboprobe showed no fluorescence. (C) CYP2D mRNA was observed in the thalamic neurons. (D) The
control section hybridized with sense probe did not reveal any fluorescent staining. (E) Expression of CYP2D mRNAwas seen in the neurons of the striatum
although to the lesser extent than the neurons of the cerebral cortex. (F) Control sections did not show any staining. (G) The anterior horn cells of the spinal
cord (arrow) were intensely fluorescent indicating the substantial expression of CYP2D mRNA. Inset depicting anterior horn cells. Scale bar = 25 Am. The
position of the central canal is indicated by arrowhead. (H) The control section hybridized with CYP2D sense riboprobe did not show any fluorescent staining.
Scale bars = 200 Am.
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Fig. 6. Immunoblot analysis of microsomal protein from rat brain regions
immunostained with antibody to rat liver P4502D1. Microsomes prepared
from the rat brain regions were subjected to SDS-PAGE followed by
immunoblotting. Lanes were loaded as rat liver (lane 1), rat brain cortex
(lane 2), cerebellum (lane 3), brainstem (lane 4), hippocampus (lane 5),
thalamus (lane 6), and striatum (lane 7). Lanes were loaded with 50 Ag of
microsomal protein except lane 1 which contained 10 Ag of the liver
microsomal protein.
S.J. Chinta et al. / Molecular Brain Research 135 (2005) 81–9286water, ad libitum. All animal experiments were carried out
in accordance with the National Institutes of Health guide-
lines for the care and use of laboratory animals. All efforts
were made to minimize animal suffering, to reduce number
of animals used, and to utilize alternatives to in vivo
techniques, if available.
2.3. Studies with human brain
Human brain tissue from a traffic accident victim with no
known neuro-psychiatric disorders was obtained from the
Human Brain Tissue Repository, Department of Neuro-
pathology, NIMHANS. Autopsy brain sample from a 55-
year-old male with postmortem delay of 6 h was used. After
autopsy, the brain was washed in ice-cold saline, the frontal
cortex was dissected out based on standard anatomical
markings, and stored at 70 8C.
2.4. RT-PCR analysis to identify the presence of additional
transcript in rat brain and liver
Total RNA was isolated from whole brain and liver of
male rats. The first strand of the cDNA was synthesized
using 1 Ag of total RNA from the rat brain and liver, oligo
dT primers and reverse transcriptase. The second strand was
synthesized using T4 DNA polymerase. The double-
stranded DNAwas purified by phenol/chloroform extraction
and alcohol precipitation. A region of the CYP2D1 cDNA
representing exons 2–4 was amplified using the forward
primer 5V-GTGACGTGTTCAGCCTGCA-3V (nucleotide
location 205–223 from ATG of AB008422) and the reverse
primer 5V-TGAACAAAGCCGTTGTGTAA-3V (nucleotide
locations 543–562 relative to ATG of AB008422). The
reaction mixture was initially denatured for 5 min at 95 8C
followed by 30 cycles of denaturing for 30 s at 94 8C,
annealing for 30 s at 60 8C and extension for 1 min at 72 8C.
The final extension was performed for 5 min at 72 8C.
Another region of the CYP2D1 cDNA representing exons
6–7 was amplified using the forward primer 5V-
GGCCAAGGGGAACCCTGAGA-3V (nucleotide location
852–871 relative to ATG of AB008422) and reverse primer
5V-GTCATACCCAGGGGGACGA-3V (nucleotide location
1171–1189 relative to ATG of AB008422). The reaction
mixture was initially denatured for 3 min at 98 8C followed
by 35 cycles of denaturing for 30 s at 94 8C, annealing for
20 s at 61.2 8C and extension for 45 s at 72 8C. The final
extension was performed for 7 min at 72 8C. The PCR
products (20 Al) were separated by electrophoresis using
1.2% (w/v) agarose gel and stained with ethidium bromide.
The identity of the PCR products was confirmed by
sequencing.
2.5. Preparation of microsomes
Animals were anaesthetized with ether and perfused
transcardially with ice-cold Tris buffer (100 mM, pH 7.4)containing KCl (1.15%, w/v) prior to decapitation and
removal of brain. Microsomes were prepared from rat
brain regions, which were dissected out using standard
anatomical landmarks. Brain regions were pooled from
8–10 rats for each experiment. Tissues were homogenized
using a Potter-Elvehjem homogenizer in 9 volumes of
ice-cold Tris buffer (0.1 mM), EDTA (0.1 mM), KCl
(1.15%, w/v), phenyl methyl sulfonyl fluoride (0.1 mM),
butylated hydroxytoluene (22 AM), glycerol (20%, v/v),
aprotinin (0.001%, w/v), and leupeptin (0.001%, w/v),
previously bubbled with nitrogen (buffer A). The homo-
genate was centrifuged at 17,000  g for 30 min at 4 8C.
Thereafter, the supernatant was centrifuged at 100,000  g
for 1 h to get the microsomal pellet. The pellet was
suspended in a small volume of buffer A, aliquoted,
flash-frozen in liquid nitrogen and stored at 70 8C. The
protein concentration was measured by dye-binding
method [4].
2.6. Immunoblot analyses
Microsomal proteins from rat brain regions (50 Ag)
were subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis [18]. Proteins were transferred from
the gel to nitrocellulose membranes [31]. Membranes
were immunostained with antiserum to liver P4502D1,
followed by incubation with anti rabbit IgG labeled with
alkaline phosphatase (Vector Laboratories, USA). The
immunostained bands were detected using nitroblue
tetrazolium and 5-bromo 4-chloro 3-indolyl phosphate as
chromogens.
2.7. Northern analysis and fluorescence in situ
hybridization
cDNA to rat liver CYP2D1 obtained as a gift from Dr. J.
P. Hardwick [10] was used for the preparation of riboprobes.
The total RNA was extracted from rat brain (cortex) and
liver as described by Chomezynski [7], separated electro-
phoretically and transferred onto positively charged nylon
membrane by capillary transfer. The membranes were UV
cross-linked and hybridized with digoxigenin-labeled anti-
Fig. 7. Localization of P4502D1 in normal rat brain by immunohistochemistry. (A) Immunostaining of cortical neurons in the rat brain section showing the
presence of P4502D1 protein. Scale bar = 10 Am. (C) Intense immunostaining of the granule cell layer of cerebellum was seen indicating the presence of
P4502D1. Scale bar = 10 Am. (E) Intense immunostaining of reticular neurons in the midbrain showing the presence of P4502D1 in rat brain. Scale bar = 10
Am. (G) The neurons in olfactory glomeruli were also specifically stained demonstrating the localization of P4502D1 protein. Scale bar = 10 Am. (B, D, F, and
H, respectively) Control sections of the above regions immunostained with non-immune serum did not show any immunostaining. Scale bar = 100 Am.
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The sense cRNA probe was synthesized using T7 polymer-
ase. The membrane was hybridized overnight with digox-
igenin-labeled sense and antisense riboprobe at 55 8C,
washed, incubated with antibody to digoxigenin fab frag-
ments conjugated with alkaline phosphatase. The bands
were visualized using chromogenic substrate for alkaline
phosphatase.
Male Wistar rats were anaesthetized and perfused trans-
cardially with normal saline followed by buffered parafor-
maldehyde (4%, w/v; 200 ml/rat) prior to the removal of
brain. The tissue was processed for paraffin embedding and
serial sections (8–10 Am thick) were cut under RNase-free
conditions. Sections were dewaxed, hydrated in graded
ethanol, acetylated, and treated with proteinase-K. The
sections were then rinsed in phosphate-buffered saline and
dehydrated using graded ethanol. Digoxigenin-labeled sense
(for control sections) and antisense cRNA probes were
synthesized from CYP2D1 cDNA using T3 and T7 RNA
polymerases, respectively. Sections were hybridized over-
night at 55 8C with sense or antisense probes. After hybrid-
ization, the sections were washed, incubated with blocking
reagent (0.5% w/v, NEN Life Sciences, USA) and incubated
with antibody to digoxigenin conjugated to horseradish
peroxidase. After washing, the sections were incubated with
biotinylated tyramide followed by streptavidin fluorescein.
Finally, the sections were washed, dried, counterstained with
PBS containing Evan’s Blue (0.01% v/v), and mounted prior
to examination under the fluorescence microscope.
2.8. Immunohistochemistry
Paraffin embedded sections of rat brains were used.
Sections were dewaxed and transferred to phosphate-
buffered saline containing hydrogen peroxide (3% v/v) to
block the endogenous peroxidase reaction. The sections
were pressure cooked in sodium citrate buffer (0.01 M, pH
6) for antigen retrieval. The sections were blocked with
normal goat serum and incubated with antiserum to hepatic
P4502D1 (diluted 1:1000 in PBS). Control sections were
incubated with non-immune serum. The sections were
washed, treated with biotinylated anti-rabbit IgG (diluted
1:1500 in PBS), and incubated with VECTASTAIN-Elite
ABC reagent. The color was developed using diaminoben-
zidine and hydrogen peroxide. Sections were washed with
water, dehydrated in graded alcohol, cleared with xylene, air
dried, and mounted using Permont before examination
under the microscope.Fig. 8. Localization of P4502D1 in normal rat brain by immunohistochemistry.
pyramidal neurons of hippocampus. Scale bar = 10 Am. (B) Positive staining of P45
10 Am. (C) CA3 neurons of hippocampus also showing the presence of P4502D1 p
non-immune serum did not show any immunostaining for P4502D1 protein. Scale
thalamus. Scale bar = 10 Am. (F) Immunolabeling was not observed in the control s
Sparsely stained striatal neurons showing the presence of P4502D1 protein in rat b
spinal cord section incubated with P4502D1 antiserum. Scale bar = 10 Am.3. Results
3.1. RT-PCR analysis for detection of splice variants of
CYP2D1 in rat liver and brain
RT-PCR experiments were performed to examine the
presence of splice variants in the region exons 2 to 4
using cDNA prepared from rat brain and liver. The
anticipated PCR product was 350 bp long representing
195–549 bp of CYP2D1. In rat brain, we observed the
formation of 2 PCR products, a 350-bp band representing
the normally spliced CYP2D1 and a 200-bp product
representing the exon 3 deleted transcript of CYP2D1
(Fig. 1). This additional band at 200 bp was not observed
in rat liver, indicating that the transcript with exon 3
deletion is not present in rat liver. We also performed RT-
PCR to detect the partial inclusion of intron 6 analogous
to that seen in human brain. We observed only one band
at 282 bp representing the normal CYP2D1 amplicon in
both rat liver and brain. As a positive control, we
simultaneously RT-PCR amplified the cDNA synthesized
from human brain cortex. Two bands of 340 bp and 282
bp were observed in human brain cDNA indicating the
presence of the brain variant CYP2D containing partial
inclusion of intron 6 (Fig. 2).
3.2. Constitutive expression of P4502D in rat brain
The constitutive expression of CYP2D in the rat brain
was examined by Northern blot analysis performed with
total RNA from rat liver and brain cortex using the
riboprobe synthesized from the cDNA to CYP2D1. North-
ern blot analysis using the T3 RNA riboprobe (antisense)
revealed the constitutive expression of CYP2D mRNA in rat
brain. The molecular mass of the transcript was approx-
imately 1.6 kb (Fig. 3). No signal was observed when
Northern blots were hybridized with the sense riboprobe,
which was synthesized from cDNA to CYP2D1 using T7
polymerase (data not shown).
3.3. Localization of CYP2D mRNA in rat brain by
fluorescence in situ hybridization
Fluorescence in situ hybridization experiments were
performed using normal rat brain sections to determine the
localization of CYP2D mRNA. Fluorescence in situ hybrid-
ization studies demonstrated the presence of CYP2D mRNA
predominantly in neuronal cells in rat brain regions, which(A) Intense immunostaining indicating the presence of P4502D in CA1
02D protein was observed in the CA2 neurons of hippocampus. Scale bar =
rotein. Scale bar = 10 Am. (D) Control section of hippocampus stained with
bar = 200 Am. (E) Presence of P4502D1 protein was seen in the neurons of
ection of thalamus treated with non-immune serum. Scale bar = 200 Am. (G)
rain. Scale bar = 10 Am. (H) Staining was observed in anterior horn cells of
S.J. Chinta et al. / Molecular Brain Research 135 (2005) 81–9290were hybridized with the riboprobe synthesized from the
cDNA to CYP2D1. A high level of CYP2D1 mRNA
expression was seen in olfactory bulb, thalamus, cerebral
cortex, and hippocampus. In the olfactory lobe, the neuronal
cells and glomeruli (inset) were intensely labeled (Fig. 4A),
whereas control section did not show any staining when
hybridized with sense probe (Fig. 4B). The neurons in the
cerebral cortex showed intense cytosolic staining, indicating
the presence of CYP2D mRNA (Fig. 4C), while the section
hybridized with sense probe did not show any fluorescence
(Fig. 4D). The laminar architecture of different cortical
layers was clearly seen in the section hybridized with
antisense probe. In the cerebellum, Purkinje cell layer
showed intense fluorescence, while the interneurons of the
molecular layer (ML) were relatively less stained (Fig. 4E).
Higher magnification of Purkinje neurons showed intense
fluorescence in the cell body of the neurons (inset). In the
midbrain, the reticular neurons were selectively labeled,
indicating the predominant presence of CYP2D mRNA
within these cell population (Fig. 4G). Intense fluorescence
was seen in hippocampus, in the pyramidal neurons of CA1,
CA2, and CA3, and in the granule cell layer in the dentate
gyrus (Fig. 5A). The thalamic neurons are also stained
intensely showing the expression of CYP2D mRNA
(Fig. 5C), whereas control section hybridized with sense
probe did not show any staining (Fig. 5D). There was only
sparse staining of neurons in the striatum (Fig. 5E). The
anterior horn cells of the spinal cord (inset) are intensely
fluorescent indicating the expression of CYP2D mRNA
(Fig. 5G), while the control section hybridized with sense
probe did not show any staining (Fig. 5H).
3.4. Immunoblot analysis of microsomes from rat brain
using antiserum to hepatic P4502D
Immunoblot studies were carried out to confirm the
presence of the P4502D in various regions of rat brain.
Immunoblot analysis of microsomes prepared from rat brain
regions using antiserum to the hepatic P4502D1 revealed
the presence of an immunoreactive protein of molecular
weight 52 kDa. The constitutive presence of P4502D was
detectable in all the rat brain regions examined. There was a
variation in the expression of P4502D among the regions
studied, more staining was seen in brainstem, hippocampus,
and thalamus and comparatively less intense staining was
observed in striatum (Fig. 6).
3.5. Immunohistochemical localization of P4502D1 in rat
brain
Immunohistochemical studies demonstrated the presence
of P4502D1 protein predominantly in neuronal cells in rat
brain. Higher magnification of cortical neurons in rat brain
expressing P4502D1 is shown in Fig. 7A. Immunostaining
of apical dendrites was also observed. No immunostaining
was seen in sections pretreated with non-immune serum(Fig. 7B). Intense immunostaining was observed in neurons
of olfactory bulb, indicating the presence of P4502D1. The
neurons in the olfactory glomeruli were also intensely
stained (Fig. 7G). No immunostaining was observed in
control sections incubated with non-immune serum
(Fig. 7H). Presence of P4502D1 protein was observed in
CA1, CA2, and CA3 subfields of hippocampus (Figs. 8A, B,
and C). P4502D1 expression was also seen in the neurons of
the anteroventral nucleus of thalamus (Fig. 8E). Sparse
staining of neurons was observed in striatum indicating the
presence of P4502D1 protein (Fig. 8G). Intense staining of
anterior horn cells in spinal cord demonstrated the con-
stitutive expression of P4502D1 in these cells (Fig. 8H).4. Discussion
Several P450 isoforms, such as CYP2D, are present in
rat brain and localize predominantly in neurons, the site
of action of most drugs [15,17,26,38]. However, the
mRNA expression does not correlate with the protein
levels. The presence of unique, tissue-specific isoforms of
P450 generated through alternate splicing provides a
mechanism by which a variety of transcripts are
generated. However, premature termination of translation
of these transcripts would results in the absence of the
functional protein.
Polymorphisms of CYP2D1 for rat and CYP2D6 for
humans have been associated with impaired oxidation of
many drugs with diverse pharmacological actions [20]. Rat
CYP2D1 and human CYP2D6 gene shares 83% homology.
There is some indication that CYP2D6 mRNA splice
variants are produced in human liver [10,11]. Studies from
our laboratory have shown the presence of the splice variant
forms of CYP2D in human brain [28]. In the present study,
we used RT-PCR to identify the presence of any such splice
variants of CYP2D1 in rat brain and liver (Fig. 1) and
discovered the presence of a splice variant with exon 3
deletion in the rat brain but not in liver. The deletion of exon
3 results in the generation of a stop codon at 391–393 bp
resulting in premature termination of translation (Fig. 1B).
Thus, the mRNA detected does not translate into a
functional protein.
Nervous system has a propensity for generating
alternate spliced forms and splicing defects cannot be
related to differences in the genomic sequence but may be
regulated by mechanisms involving spliceosomal complex
and RNA binding proteins, which are poorly understood
[12]. An alternate spliced form of flavin-containing
monooxygenase (FMO4) with exon 4 deletion is seen in
rat brain but not in other tissues [16]. The tendency for rat
brain to generate alternate spliced genes is seen in the
present study wherein an alternate spliced variant having
exon 3 deletion was identified only in the rat brain and
not in liver. Screening of a human cDNA library revealed
the presence of three variants namely, exon 3 deletion,
S.J. Chinta et al. / Molecular Brain Research 135 (2005) 81–92 91partial inclusion of intron 6 and a third having both the
deletion and inclusion [28]. However, the splice variant
with partial inclusion of intron 6 detected in human brain
was not observed in rats while the variant with exon 3
deletion was detected (Fig. 2).
The alternate spliced variants containing exon 3 deletion
have a premature stop codon, which prevents their trans-
lation into functional gene products. Thus, estimation of
P450 isoforms by studying gene expression alone using
Northern blotting, RT-PCR, and in situ hybridization
[12,16,19] would represent contributions from functional
and prematurely terminated genes and would potentially
over-estimate the expression of a particular isoform. This
could explain the high levels of expression CYP2D1 mRNA
seen in the present study, but not the corresponding protein.
High levels of expression of a P450 mRNA with no
accumulation of the corresponding protein have been
convincingly demonstrated in the case of P4502C13 in the
livers of rats [22]. This study also demonstrates that within
the same species there exists a difference in expression of
P450 alternate spliced forms in brain and liver.
In conclusion, the study demonstrates the significant
differences that exist in the presence of alternate spliced
forms in liver and brain. The presence of as yet unidentified
P450 forms generated by alternate splicing would help
understand the specific biotransformation pathways occur-
ring at the target site of action of drug(s). It further indicates
that CYP2D1 mRNA is widely and constitutively expressed
in neuronal cells in the rat brain. Identification of new
isoforms of P450 at target site needs an in depth analysis of
at the mRNA and protein level. Several hepatic forms, such
as, CYP1A2, 2B1, 2B2, 3A1 [30], 2C6, 2C11, 2C12, 2C23,
and 2E1 [39], have been detected by PCR, but the
corresponding proteins may contribute very little to the
overall content of brain P450.Acknowledgments
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